Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

BACKGROUND: COU-AA-301 trial has proved that abiraterone acetate (AA), a selective inhibitor of androgen biosynthesis, improved overall survival (OS) of patients with metastatic castration resistant prostate cancer (mCRPC) after a first line of docetaxel. Based on this result, a Temporary Authorizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Houédé, Nadine, Beuzeboc, Philippe, Gourgou, Sophie, Tosi, Diego, Moise, Laura, Gravis, Gwenaëlle, Delva, Remy, Fléchon, Aude, Latorzeff, Igor, Ferrero, Jean-Marc, Oudard, Stéphane, Tartas, Sophie, Laguerre, Brigitte, Topart, Delphine, Roubaud, Guilhem, Agherbi, Hanane, Rebillard, Xavier, Azria, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392747/
https://www.ncbi.nlm.nih.gov/pubmed/25884302
http://dx.doi.org/10.1186/s12885-015-1257-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392747/
https://www.ncbi.nlm.nih.gov/pubmed/25884302
http://dx.doi.org/10.1186/s12885-015-1257-2

Ejemplares similares